Abstract
Gliomas are malignant tumors that originate from the central nervous system. The aldehyde dehydrogenase (ALDH) family has been documented to affect cancer progression; however, its role in gliomas remains largely unexplored. Bulk RNA-seq analysis and single-cell RNA-Seq analysis were performed to explore the role of the aldehyde dehydrogenases family in gliomas. Training cohort contained The Cancer Genome Atlas data, while data from Chinese Glioma Genome Atlas and Gene Expression Omnibus were set as validation cohorts. Our scoring system based on the aldehyde dehydrogenases family suggested that high-scoring samples were associated with worse survival outcomes. The enrichment score of pathways were calculated by AUCell to substantiate the biofunction prediction results that the aldehyde dehydrogenases family affected glioma progression by modulating tumor cell proliferation, migration, and immune landscape. Tumor immune landscape was mapped from high-scoring samples. Moreover, ALDH3B1 and ALDH16A1, two main contributors of the scoring system, could affect glioblastoma cell proliferation and migration by inducing cell-cycle arrest and the epithelial-mesenchymal transition. Taken together, the aldehyde dehydrogenases family could play a significant role in the tumor immune landscape and could be used to predict patient prognosis. ALDH3B1 and ALDH16A1 could influence tumor cell proliferation and migration.
Introduction
Gliomas represent the most prevalent and aggressive primary malignancies of the central nervous system. Despite therapeutic advancements, the prognosis for high-grade glioblastoma (GBM) remains poor, with median survival hovering around 15–18 months. Traditional histological classifications often fall short of providing precise prognostic predictions or guiding personalized treatment. The ALDH family, known for detoxifying aldehydes and influencing cancer stem cells, has shown significance in various cancers, but its specific impact on the glioma microenvironment and progression required deeper investigation.
Methodology
This study utilized a multi-omic approach to characterize the ALDH family's role in glioma:
- Bioinformatics & Modeling: Researchers applied LASSO (Least Absolute Shrinkage and Selection Operator) regression to identify a 5-gene prognostic signature (ALDH2, ALDH5A1, ALDH3B1, ALDH3A1, and ALDH16A1) from the broader 19-member family.
- Single-Cell & Immune Profiling: Single-cell RNA-seq data was analyzed using AUCell and GSVA to map gene expression to specific cell types. Immune infiltration was quantified using tools like CIBERSORT and ESTIMATE.
- Experimental Validation: siRNA-mediated knockdown of key risk genes (ALDH3B1 and ALDH16A1) was performed in human glioma cell lines, followed by functional assays including CCK8 for proliferation and Transwell for migration.
Datasets
The study integrated several large-scale datasets to ensure robustness:
- Training Cohort: The Cancer Genome Atlas (TCGA), featuring 522 lower-grade glioma (LGG) and 150 GBM samples.
- Validation Cohorts: Two datasets from the Chinese Glioma Genome Atlas (CGGA) and one from the Gene Expression Omnibus (GEO; GSE108474).
- Single-Cell Data: GSE139448 for high-resolution cellular mapping within GBM tumors.
Key Insights and Results
The analysis revealed a complex interplay between ALDH expression and glioma malignancy. The 5-gene risk model demonstrated exceptional prognostic accuracy, achieving an Area Under the Curve (AUC) of 0.882 for 3-year survival in the TCGA cohort.
The "Risk" Signature and Clinical Correlation
The model identified a dichotomy within the ALDH family: ALDH2 and ALDH5A1 acted as protective factors, while ALDH3B1 and ALDH16A1 were associated with increased risk. High risk scores were significantly correlated with more aggressive clinical features, including higher tumor grade (G4), IDH-wildtype status, and the mesenchymal molecular subtype.
Reshaping the Immune Microenvironment
High-risk tumors were characterized by an immunosuppressive landscape, showing increased infiltration of M2 macrophages and Regulatory T cells (Tregs). Furthermore, these high-risk samples exhibited elevated expression of immune checkpoints such as PD-1, CTLA-4, and CD80, suggesting potential sensitivity to immunotherapy.
Functional Drivers: ALDH3B1 and ALDH16A1
In vitro experiments confirmed that silencing ALDH3B1 or ALDH16A1 inhibited glioma cell proliferation and migration. Mechanistically, these genes were found to promote the Epithelial-Mesenchymal Transition (EMT) and regulate the cell cycle, with knockdown leading to G2/M phase arrest.
Discussion and Future Directions
The ALDH-based risk score provides a robust tool for predicting glioma prognosis and understanding the tumor's immune landscape. While the study offers strong in vitro evidence, future work should include in vivo validation using xenograft models to confirm these findings in a physiological context. Additionally, further research is needed to delineate the specific signaling pathways through which ALDH enzymes drive EMT and cell cycle progression. Translating this scoring system into clinical practice will require prospective trials to validate its utility in guiding personalized treatment strategies.
Summary updated